Top FemTech Companies by Funding and Reach

VC investment in femtech quadrupled from $600 million in 2015 to nearly $2.4 billion in 2021, per FemTech Analytics. Silicon Valley Bank tracked $2.6 billion in women's health funding in 2024, set against a backdrop where only 4% of biopharma R&D had historically addressed female-specific conditions. Those two figures describe a market failure so obvious it's almost embarrassing. Investors, eventually, noticed.

The employer-benefits model was the pivotal catalyst. When fertility benefits adoption among large U.S. employers reached 40% in 2024, it handed B2B femtech companies a scalable, recurring revenue path with identifiable procurement cycles. A compelling mission doesn't close a Series C; a replicable sales motion does. Femtech finally stopped being a passion project and started being a profit proposition — and with a market this large, that's no small delivery.

But how concentrated has that capital actually been? Average deal sizes rose from $11.6 million in 2022 to $24.3 million in 2024, then contracted to $15.4 million in 2025. The 2024 spike is largely explained by two rounds: Flo Health's $200 million and Maven's $125 million together accounted for 43% of that year's total femtech funding. Only 16% of femtech deals in 2024 exceeded $50 million, yet those five rounds captured 66% of total capital. There is a pronounced mid-stage funding gap at the Series B level, and it shows little sign of narrowing.

The 2025 and 2026 trajectory reinforces this. Dealroom tracked $724 million in 2025; with $239 million raised in the first half of 2026, the full year is pacing toward roughly $478 million, a projected decline of about a third versus 2025. The mega-round era appears to be moderating. That matters for everything that follows, because the companies profiled below built their leads during the capital-abundant phase. Their advantage is now durable largely because the environment capable of producing a credible challenger has materially changed.

The Geographic Concentration of Femtech Capital and Company Formation

Of roughly 4,340 femtech companies globally, 1,140 are funded. Only 281 have reached Series A or above. The United States leads in company count, with 1,269 femtech companies per Tracxn data, followed by India and the United Kingdom. North America accounted for a majority of global femtech revenue in 2025, per Fortune Business Insights.

That concentration has a structural explanation: the employer-benefits payer model concentrates value in the U.S. market, because that's where large self-insured employers make billion-dollar benefits decisions. If your product lives inside an HR portal procured by a benefits team in New York or Dallas, U.S. geography is less a preference and more a precondition.

But that framing is already becoming obsolete. Flo Health, incorporated in the UK with Belarusian founding roots, has outscaled every American consumer app by an embarrassing margin. Natural Cycles, a Swedish company, holds regulatory clearances that American competitors spent years and substantial capital attempting to replicate. Europe's regulatory frameworks, habitually characterized as friction, are functioning as competitive moats.

Asia-Pacific is forecast to expand at the fastest regional growth rate through the early 2030s, driven by smartphone penetration and menstrual-health app adoption. It has yet to produce funded leaders at the scale of the U.S. and European companies examined here, but the framing of femtech as an Anglo-American phenomenon has a shelf life, and that shelf life is shorter than current capital allocation patterns suggest.

Flo Health: The Largest Consumer Reach in Femtech, and It Isn't Close

Flo is, by a significant margin, the most-used femtech product on earth: over 380 million downloads worldwide and over 70 million monthly active users as of late 2024. No other company in this field is playing the same game on the same field. That's worth stating plainly before analyzing it, because the scale tends to get normalized in competitive comparisons where it shouldn't be.

Flo raised more than $200 million in a Series C from General Atlantic in July 2024, reaching unicorn status above a $1 billion valuation. Gross bookings were expected to exceed $200 million in 2024, reflecting approximately 50% year-over-year growth through a freemium-to-premium conversion model.

Two structural factors explain the position. Menstrual tracking is a daily behavior with habitual reinforcement: users open the app every day, log every cycle, and accumulate years of personal health history that is costly to migrate elsewhere. That switching cost is underappreciated by analysts who focus on feature comparisons. Second, Flo's global distribution demonstrates that consumer-facing femtech is not bounded by the American employer-benefits market, a distributional fact its enterprise-focused competitors cannot easily replicate no matter how well-capitalized they become.

That said, Flo was sued for sharing users' sensitive health data with third parties, including Google and Meta, without consent. Flo and Google settled for a combined $56 million; a jury found Meta liable in 2025. In 2025, Flo adopted Databricks for analytics and AI-powered personalized cycle predictions. The company's response to a data-handling scandal is to build more sophisticated data infrastructure. That's not necessarily wrong, but it does clarify the core tension: Flo's greatest asset and its greatest exposure are the same thing. The product is intimate health data. The liability is also intimate health data. There is no version of Flo's business model that resolves that cleanly.

Maven Clinic: Highest Valuation Among Private U.S. Femtech Companies, and a Retention Story Worth Examining Carefully

Maven Clinic closed a $125 million Series F in October 2024, led by StepStone Group with participation from General Catalyst, Sequoia, and Oak HC/FT, bringing total funding past $425 million at a $1.7 billion valuation. The platform covers the full reproductive life cycle: fertility, pregnancy, postpartum, pediatrics, menopause. Approximately 17 million covered lives across over 2,000 enterprise relationships, including Amazon, Microsoft, and AT&T. A reported 98% enterprise customer retention rate.

Sacra estimated Maven was tracking toward $268 million in annual recurring revenue for 2024, up 26% year-over-year, at a 6.9x forward revenue multiple. Investors are pricing the trajectory, not the current economics.

Then, in November 2024, shortly after closing the Series F, Maven announced a 10% workforce reduction. Closing a large round and cutting headcount in rapid succession invites uncomfortable questions about the cost structure underneath a 98% retention rate. It doesn't disqualify the model. It does complicate the story, and anyone who tells you otherwise is doing you a courtesy you probably don't need.

Maven's fastest-growing segment is its Menopause and Midlife program, up 300% year-over-year with more than 550 clients. Menopause was largely absent from femtech offerings five years ago. Its emergence as a high-growth employer benefit reflects belated recognition that women's health doesn't conclude at 40, and that unmanaged menopause symptoms carry measurable productivity costs that employers are now actively quantifying. The Amazon account switch from Progyny to Maven in September 2024 is a meaningful competitive signal; Amazon's procurement behavior operates in its own category, but a named departure from the only public company in the space is not nothing.

The investor roster includes Oprah Winfrey, Mindy Kaling, and Reese Witherspoon alongside institutional backers. Whether celebrity capital brings anything beyond press coverage is a question the retention numbers don't answer.

Kindbody: The Highest Femtech Valuation on Record, and the Most Complicated Story in the Field

Kindbody holds a Series D valuation of $1.8 billion from 2023, the highest femtech valuation on record. It has raised more than $300 million in total debt and equity, with key investors including JP Morgan Chase's Morgan Health, GV (formerly Google Ventures), and Perceptive Advisors.

The model is structurally distinctive. Kindbody owns and operates fertility clinics, including egg freezing and IVF services, while simultaneously selling employer fertility benefits. As of mid-2025, it operated 27 signature clinics and IVF labs, plus over 400 partner clinics across more than 100 countries, serving 135 employers. Sacra estimated $180 million in 2023 revenue, growing approximately 50% year-over-year. Egg freezing is offered at roughly $6,000 per cycle versus traditional clinic rates that are multiples higher.

Bloomberg reported in September 2025 that Kindbody faced a financial crisis, burning cash at a rate inconsistent with its valuation. Bloomberg's investigative podcast, "IVF Disrupted: The Kindbody Story," documented alleged clinical errors, including mislabeled, lost, and accidentally destroyed embryos.

These are not abstract operational failures. They concern the handling of reproductive material, which carries consequences of an entirely different order than a buggy software update. Any high-volume clinical operation is exposed to procedural error, and that's fair. But the specific nature of the errors documented, and their irreversibility, is what makes Kindbody's story qualitatively different from a typical high-growth company working through execution challenges. Kindbody illustrates the central cost of vertical integration in clinical settings: you own the margin advantage and you own the execution risk. The digital-only platforms in this field carry neither. That asymmetry is not a coincidence.

Progyny: The Only Public Femtech Company and the Employer-Benefits Benchmark at Revenue Scale

Progyny is the grounding reference point for this entire analysis, and not just because of its size. It is the only company in this ranking whose financials are audited, disclosed quarterly, and subject to the corrective mechanism of public market pricing. The valuations discussed elsewhere in this piece are estimates, Sacra projections, or investor-disclosed round terms. Progyny's numbers have been reviewed by accountants and scrutinized by analysts who get paid to be skeptical. That distinction is underappreciated in how femtech coverage treats these companies as comparably legible.

Founded in 2008, Progyny went public on NASDAQ under the ticker PGNY in 2019. The company manages fertility, family building, and women's reproductive health benefits for large employers, serving employers with a combined 7.2 million employees. As of early 2025: $1.14 billion in trailing twelve-month gross revenue, 2% year-over-year growth, a market capitalization of $1.88 billion, a revenue multiple of approximately 1.08x, and 20% gross margins.

Compare that 1.08x multiple to Maven's estimated 6.9x forward revenue multiple. What does Maven look like at Progyny's revenue scale, at Progyny's growth rate, under public scrutiny? The 20% gross margin at Progyny is instructive context for evaluating models that are still in high-burn phases and haven't had to answer for their cost structures in an earnings call.

The Amazon account switch to Maven is the clearest concrete evidence of competitive pressure Progyny faces from venture-backed challengers who can price aggressively while losses remain acceptable to their investors. Progyny answers to quarterly earnings calls instead. There is no equivalent of a down round when expectations meet reality in a public market; the bill arrives and asking to see it again is simply not an option.

Natural Cycles: Regulatory Moat as a Funding and Reach Strategy in Digital Contraception

Natural Cycles has raised $99.5 million across six rounds, including a $55 million Series C in May 2024 led by Lauxera Capital Partners. In a field where competitors have raised two, three, or four times that amount, the company would appear outgunned. That framing misses the point entirely.

Natural Cycles holds both FDA clearance in the United States and CE marking in Europe for its app-based contraception product, which uses basal body temperature data and an algorithm to identify fertile and non-fertile days. It is the only digital contraceptive app to hold both clearances. That regulatory fact defines a category of one in the two largest femtech markets on earth.

A well-funded entrant with a superior algorithm still faces years of clinical trials, regulatory submissions, and agency review before it can legally market its product as a contraceptive rather than a wellness tracker. Even Flo, with 380 million downloads and 70 million monthly active users, cannot position its product as contraception in the U.S. or European markets. Natural Cycles can. Clinical-grade positioning commands higher willingness to pay and opens reimbursement pathways that wellness apps cannot access regardless of their user base or capital reserves. Natural Cycles' regulatory clearance is less a certificate on the wall and more a drawbridge pulled up behind it — one that took years to build and cannot be replicated quickly.

Natural Cycles' user numbers are more modest than Flo's or Maven's. But the addressable population for a cleared contraceptive device is defined by regulatory geography and clinical indication, not app store rankings. The company built the one competitive advantage that money alone cannot replicate quickly, and it did so on less capital than any other company in this ranking. Whether it constitutes a replicable model or an idiosyncratic outcome specific to contraception's regulatory dynamics is the more interesting question, and one this field hasn't seriously grappled with yet. It's some of both.

What the Funding and Reach Tiers Reveal About Where Femtech Is Actually Heading

Two distinct winner profiles have emerged, and they are not converging.

Consumer reach leaders, exemplified by Flo, operate on massive global user bases monetized through freemium conversion. They can be built from outside the United States. They become capital-efficient relative to their scale once network effects are established. And they carry a data-trust risk that is structurally inseparable from their core value proposition: the product is health data, and the liability is also health data.

Enterprise benefits leaders, exemplified by Maven, Kindbody, and Progyny, compete on covered-lives metrics, employer contracts, and recurring revenue tied to procurement cycles. They are concentrated in the U.S. market, operationally intensive, and their competitive dynamics increasingly involve pricing pressure from venture-backed challengers running against a publicly traded benchmark that cannot absorb unlimited losses indefinitely.

Capital is concentrating further, not dispersing. Of roughly 4,340 femtech companies globally, only 281 have reached Series A or above. The gap between the companies profiled here and the rest of the field shows little sign of narrowing under current funding conditions; if anything, the contraction in average deal sizes suggests it is widening.

The menopause signal is the most practically useful near-term indicator of where the category is heading. Maven's fastest-growing program is menopause, expanding 300% year-over-year from a near-zero baseline five years ago. That is the leading edge of a use-case expansion that most femtech market-size projections have not yet fully incorporated. The estimates cited at the outset of this piece are likely undercounting the menopause addressable market, because those models were built before employer adoption accelerated to its current pace.

Kindbody's reported cash pressures and Progyny's public-market multiple of roughly 1x revenue tell a coherent joint story. Private-market growth premiums assigned to enterprise femtech companies assume a trajectory toward Progyny-scale revenue. Progyny's actual trading multiple suggests that destination is worth considerably less than private-market pricing implies. That is not an argument for pessimism about the sector. It is an argument for interrogating which business models generate durable margin at scale, before those models have to prove it publicly and discover the answer isn't what they expected.

Natural Cycles addressed that question most directly, on the least capital of any company in this ranking. Regulatory moat, clinical-grade positioning, capital efficiency. It complicates the assumption that femtech leadership is primarily a function of how much money you raise. Sometimes the door that costs the most to open isn't the one worth walking through.